4d pharma spac8/13/2023 ![]() 4D pharma’s clinical programmes are targeting cancer, including a clinical collaboration with Merck & Co., respiratory diseases including COVID-19 and asthma, gastrointestinal diseases, and pre-clinical programmes targeting neurological diseases such as Parkinson’s disease, and autoimmune diseases in addition, the Company has a research collaboration with MSD (Merck & Co.) in the field of vaccines. It is developing an extensive pipeline with multiple Live Biotherapeutic drug candidates in the clinic and has presented world-first proof of concept data in multiple indications. Immediately following the merger, existing 4D pharma shareholders will own approximately 86.9% of 4D pharma plc.There is no intention to change the strategic direction or operations of 4D pharma as a result of this transaction, and all existing 4D pharma Directors will continue to serve in their current roles.ĤD pharma is at a pivotal time of its growth and development. The merger is priced at an agreed valuation of £1.10 per 4D pharma ordinary share, representing an 18% premium on the previous day’s closing price. This is subject to approval of 4D pharma and Longevity shareholders, and the SEC review process. It is currently planned for the merger to be completed and effective in early 2021, and 4D pharma ADSs will begin trading on NASDAQ immediately following completion. In addition, 4D pharma may also benefit from the proceeds of warrants to purchase Longevity shares worth up to $23 million. This extends 4D pharma’s current operational runway into Q3 2021. 4D pharma will become dual-listed and ordinary shares will continue to be traded on AIM under the ticker symbol ‘DDDD’.ĤD pharma will benefit from the $14.6 million cash held by Longevity. As a result of the merger, 4D pharma plans to launch a new NASDAQ-listed American Depositary Share (ADS) programme under the ticker symbol ‘LBPS’ and will immediately be admitted to trading on NASDAQ upon completion. The deal is worth up to $37.6 million to 4D pharma. Nevertheless, all content published by Proactive is edited and authored by humans, in line with best practice in regard to content production and search engine optimisation.4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) – a novel class of drug derived from the microbiome – and Longevity Acquisition Corporation (NASDAQ: LOAC) (“Longevity”), a NASDAQ-listed Special Purpose Acquisition Company (“SPAC”), today announce the proposed merger of the two companies. Proactive will on occasion use automation and software tools, including generative AI. The team also has access to and use technologies to assist and enhance workflows. Our human content creators are equipped with many decades of valuable expertise and experience. Proactive has always been a forward looking and enthusiastic technology adopter. The team delivers news and unique insights across the market including but not confined to: biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto and emerging digital and EV technologies. This is content that excites and engages motivated private investors. We are experts in medium and small-cap markets, we also keep our community up to date with blue-chip companies, commodities and broader investment stories. Proactive news team spans the world’s key finance and investing hubs with bureaus and studios in London, New York, Toronto, Vancouver, Sydney and Perth. All our content is produced independently by our experienced and qualified teams of news journalists. Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience.
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |